CARsgen Therapeutics Holdings Ltd. (HK:2171) has released an update.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
CARsgen Therapeutics Holdings Ltd. announced promising results from a pivotal Phase II clinical trial for their CAR T-cell therapy, satricabtagene autoleucel, in treating advanced gastric and gastroesophageal junction cancers. The study demonstrated a statistically significant improvement in progression-free survival, positioning satri-cel as a potential first-in-class treatment. With this advancement, CARsgen continues to enhance its reputation in innovative cancer therapies, focusing on solid tumors.
For further insights into HK:2171 stock, check out TipRanks’ Stock Analysis page.